effector_inline_fullcolor_rgb_300.jpg
eFFECTOR Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
September 06, 2022 08:30 ET | eFFECTOR Therapeutics, Inc.
SAN DIEGO and REDWOOD CITY, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs)...
effector_inline_fullcolor_rgb_300.jpg
eFFECTOR Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 09, 2022 16:01 ET | eFFECTOR Therapeutics, Inc.
Presented positive interim results at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial Appointed Doug Warner, M.D., as chief medical officer SAN DIEGO and REDWOOD...
effector_inline_fullcolor_rgb_300.jpg
eFFECTOR Therapeutics Appoints Douglas Warner, M.D., as Chief Medical Officer
August 08, 2022 05:30 ET | eFFECTOR Therapeutics, Inc.
SAN DIEGO and REDWOOD CITY, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (“STRIs”)...
effector_inline_fullcolor_rgb_300.jpg
eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference
June 07, 2022 08:00 ET | eFFECTOR Therapeutics, Inc.
SAN DIEGO and REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company pioneering the development of selective translation...
effector_inline_fullcolor_rgb_300.jpg
eFFECTOR Therapeutics Reports Positive Interim Results in Zotatifin (eFT226) Phase 1/2 Clinical Trial at ASCO 2022 Showing Safety and Tolerability, and Initial Signals of Clinical Activity
June 05, 2022 17:00 ET | eFFECTOR Therapeutics, Inc.
Two partial responses observed in heavily pre-treated ER+ breast cancer patients One ongoing cohort in ER+ breast cancer has been expanded and new expansion cohort planned in ER+ breast cancer...
effector_inline_fullcolor_rgb_300.jpg
eFFECTOR Therapeutics to Present Interim Data from Ongoing Zotatifin Phase 1/2 Dose Escalation and Expansion Trial at 2022 ASCO Annual Meeting
May 26, 2022 17:15 ET | eFFECTOR Therapeutics, Inc.
Positive initial data demonstrated pharmacologically relevant exposures Management and key opinion leaders to present complete results and provide update on expanded development of zotatifin in...
effector_inline_fullcolor_rgb_300.jpg
eFFECTOR Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 10, 2022 16:02 ET | eFFECTOR Therapeutics, Inc.
Plan to present data at ASCO 2022 from ongoing zotatifin Phase 1/2 dose escalation and expansion trial Intend to provide an update on expanded development of zotatifin SAN DIEGO and REDWOOD CITY,...
effector_inline_fullcolor_rgb_300.jpg
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
May 02, 2022 16:04 ET | eFFECTOR Therapeutics, Inc.
SAN DIEGO and REDWOOD CITY, Calif., May 02, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company pioneering the development of selective translation...
effector_inline_fullcolor_rgb_300.jpg
eFFECTOR Therapeutics Announces Transition in Clinical Leadership
April 04, 2022 08:30 ET | eFFECTOR Therapeutics, Inc.
Premal Patel, M.D., Ph.D., chief medical officer, has resigned to pursue a new career opportunity Robert Sikorski, M.D., Ph.D., to take on expanded role as senior clinical development advisor SAN...
effector_inline_fullcolor_rgb_300.jpg
eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
March 16, 2022 16:01 ET | eFFECTOR Therapeutics, Inc.
SAN DIEGO and REDWOOD CITY, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs)...